Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf186 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Hsin-Yun Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Hauptthemen laut MEDLINE: HIV Infections, Emtricitabine, Anti-HIV Agents, Heterocyclic Compounds, 4 or More Rings. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Taiwan Centers for Disease Control.
Abstract (Originalsprache)
Objectives
This open-label, randomized clinical trial determined plasma bictegravir trough concentration (Ctrough) and compared virological efficacy with daily bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) versus BIC/FTC/TAF taken five-days-on-two-days-off (FOTO) in people with HIV (PWH).
Methods
Sixty PWH aged ≥20 years with plasma HIV RNA load (PVL) of <50 copies/mL for ≥6 months after having received daily BIC/FTC/TAF were randomized (1:1) to daily versus FOTO BIC/FTC/TAF. The primary endpoint was plasma bictegravir Ctrough above the in vitro protein-adjusted 95% effective concentration (162 ng/mL) at Weeks 4, 28 and 52. The secondary endpoints were PVL < 50 copies/mL and weight and renal and metabolic parameters at the same time points. After Week 52, all participants entered the 48-week extension phase to receive FOTO BIC/FTC/TAF.
Results
There were no significant differences in the baseline clinical characteristics, including drug-metabolizing gene polymorphisms, between the two groups. In the FOTO group, 90%, 93.3% and 100% of participants achieved a bictegravir Ctrough of >162 ng/mL at Weeks 4, 28 and 52, respectively. In intention-to-treat analysis, PVL of <50 copies/mL at Weeks 4, 28 and 52 was achieved by 100%, 93.3% and 100%, respectively, in the FOTO group, compared with 96.7%, 93.3% and 96.7% in the daily group. All five participants in the FOTO group with bictegravir Ctrough of <162 ng/mL at Weeks 4 and 28 maintained PVL <50 copies/mL. Of 57 (95.0%) participants who entered the extension phase, 56 (98.2%) completed the study and all maintained PVL <50 copies/mL at extension Week 48.
Conclusions
We showed PWH could successfully maintain sufficient bictegravir exposure and virological suppression with FOTO BIC/FTC/TAF. Clinical Trials Registration NCT06773754.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
- School of Pharmacy, National Taiwan University College of Medicine, Taipei, Taiwan.
- The Metabolomics Core Laboratory, Centers of Genomic and Precision Medicine, National Taiwan University, Taipei, Taiwan.
- Department of Medical Research, The Tenth Core Lab, National Taiwan University, Taipei, Taiwan.
- Department of Pharmacy, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
- Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan.
ORCID-Profile: Hsin-Yun Sun, Ching-Hua Kuo, Chien-Ching Hung
Förderung
- Taiwan Centers for Disease Control
Zitieren
APA
Sun, H. Y., Lin, Y. T., Chang, W. C., Liu, W. C., Su, Y. C., Kuo, C. H., & Hung, C. C. (2025). Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf186
Vancouver
Sun HY, Lin YT, Chang WC, Liu WC, Su YC, Kuo CH, et al. Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf186
BibTeX
@article{Sun2025,
author = {Sun, Hsin-Yun and Lin, Ya-Ting and Chang, Wen-Chi and Liu, Wen-Chun and Su, Yi-Ching and Kuo, Ching-Hua and Hung, Chien-Ching},
title = {Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf186}
}
EUVIMED